

# PICC-Related Upper Extremity Deep Vein Thrombosis (UEDVT)

## Prevalence

### UEDVT Prevalence<sup>1</sup>

Approximately 10% of all DVTs involve upper extremities

#### Primary (20%)

- Venous Thoracic Outlet Syndrome
- Effort-related thrombosis (Paget-Schroetter Syndrome)
- Idiopathic

#### Secondary (80%)

- Catheter-related thrombosis
- Cancer-associated thrombosis
- Surgery or trauma of the arm or shoulder
- Hormone-induced coagulation abnormalities (i.e. pregnancy)


### PICC-Related UEDVT Incidence Rates<sup>2</sup>

Symptomatic PICC-related DVTs

- 1-4% incidence
- Asymptomatic + symptomatic PICC-related DVTs
  - Up to 38% incidence
- Median time to thrombus: 8 to 12 days

38% Rate of Symptomatic AND Asymptomatic PICC-Related DVTs

1-4% Rate of Symptomatic PICC-Related DVTs



## Relevance

### UEDVT Relevance Compared to Other Catheter Complications

- **Catheter-Related Bloodstream Infections (CRBSIs):** Less than 2.2% of PICCs have CRBSIs (per 100 catheters)<sup>3, 4</sup>
- **Occlusions:** Approximately 25% of catheters may become occluded<sup>5</sup>
- **DVTs:** Asymptomatic + symptomatic PICC-related DVTs have shown a rate as high as 38%<sup>2</sup>

## Venous Thrombosis Risks<sup>6</sup>

### Patient and Vascular

Catheter-Associated Infection  
Fibrinous Catheter Lumen Occlusion  
Extrinsic Vascular Compression  
Age Extreme (Old/Young)

### Technical

Larger Catheter Diameter  
Multi-Lumen Catheters  
Catheter Tip Malposition  
Two or More Insertion Attempts  
Left-Sided Placement  
Subclavian Vein Insertion

### Treatment-Related

L-Asparaginase  
Estrogen or Progesterone Agents  
Recombinant Human Interleukin-2  
Granulocyte-Macrophage CSF  
Thalidomide

## Sequelea of UEDVT <sup>7,8</sup>

If a catheter-related venous thrombus develops, between the catheter and vessel wall, it may:

- Lead to complete blockage of the vein
- Become a life-threatening condition (pulmonary embolism)
- Have potential complications including, but not limited to, post-thrombotic syndrome

## UEDVT Link to Infection and Occlusion <sup>8,9,10,11</sup>

- CVC placement provides a rich culture for bacterial growth because of foreign body response upon insertion of CVC
- As the biofilm layer develops it encloses and protects bacteria, which can lead to an increased risk of infection
- Post-mortem evaluation of 72 cancer patients with CVCs showed a strong correlation between catheter-related sepsis and CVC thrombosis
  - A fibrin layer was present on ALL catheters
  - Catheter-related thrombosis was present in 38% of cases
    - 23% of these had sepsis
    - No patients without catheter-related thrombosis had sepsis

PICC-related UEDVT is a significant clinical issue, has a very high prevalence rate compared to the other primary catheter-related complications and can lead to serious complications. Let this knowledge be your stepping stone in heightening your awareness of DVTs and the relationship to PICCs.

---

AngioDynamics retains a highly credentialed team of clinical specialists committed to providing educational support and training.

To learn more about our UEDVT accredited program,  
“Reaching New Heights in Understanding CVC Complications: Heighten Your DVT Awareness”  
call 1.800.833.9973 or go to [www.angiodynamics.com](http://www.angiodynamics.com)

---

#### REFERENCES

1. Kutcher, N., “Deep vein thrombosis of the upper extremities,” *The New England Journal of Medicine*, 2011, 364(9):861-869.
2. Allen, A., “Venous thrombosis associated with the placement of peripherally inserted central catheters”, *Journal of Vascular and Interventional Radiology*, 2000, 11:1309–1314.
3. Crnich, C.J., Maki, D.J., “The promise of novel technology for the prevention of intravascular device-related bloodstream infection. II. Long-term devices”, *Clinical Infectious Diseases*, Vol 34, No. 10, May 15, 2002, pp. 1362-1368.
4. Cummings-Winfield, Cynthia, “Restoring Patency to Central Venous Access Devices”, *Clinical Journal of Oncology Nursing*, 2008, 12 (6): 925-934.
5. Stephens, L.C., et al., “Are clinical signs accurate indicators of the cause of central catheter occlusion?” *Journal of Parenteral Nutrition*, 1995, 9:75-79.
6. JNCCN, 2006, 4:889-901
7. The Oley Foundation, <http://www.oley.org/lifeline/95-065.html>, Accessed 6/25/11.
8. Wingerfer, L., Vascular Access Device Thrombosis. *Clinical Journal of Oncology Nursing*, 2003, 7:345-348.
9. Cathflo® Brochure.
10. Nifong, T., “Infection or clot – which comes first?” 22nd Annual Scientific Meeting of the Association for Vascular Access, Point/Counter Point Presentation, 9/11/08.
11. Raad, I., “The Relationship Between the Thrombotic and Infectious Complications of Central Venous Catheters”, *JAMA*, 1994.

---

Consult your AngioDynamics representative for country specific product availability.



USA > 14 Plaza Drive, Latham, NY 12110 > tel: 800-772-6446 > fax: 518-798-1360 > Canada tel: 800-268-0184  
International > Haaksbergweg 75 (Margrietoren), 1101 BR, Amsterdam Z-O > The Netherlands  
tel: +31 (0)20 753 2949 > fax: +31 (0)20 753 2939

[www.angiodynamics.com](http://www.angiodynamics.com)